补肾活血化瘀法治疗良性前列腺增生临床疗效Meta分析

打开文本图片集

[中图分类号]R249；R697+.32［文献标志码］A [文章编号]0256-7415（2025）24-0152-09

DOl：10.13457/j.cnki.jncm.2025.24.026

Meta-Analysis of Clinical Efficacy of Bushen Huoxue Huayu Therapy for Benign Prostatic Hyperplasia

YANYongting，FU Wei，LINMeixin，WUSirui

TheSeventh ScholofClinicalMedicine，Guangzhou UniversityofChinese Medicine，Shenzhen Guangdong 518133，China

Abstract：Objective：To evaluate systematically the clinical eficacy of Bushen Huoxue Huayu therapy in the treatment of benign prostatic hyperplasia（BPH） by evidence-based medicine.Methods：Randomized controled trials regarding Bushen Huoxue Huayu therapyfor BPH were retrieved from China National Knowledge Infrastructure（（CNKI）， Wanfang Data，VIP Database，SinoMed，Webof Science，TheCochrane Library，Embase，andPubMed from their inception to August 2O025.Two reviewers independently screened the literatureaccording to the inclusion and exclusion criteria and extracted the data；Meta-analysis was then performed with RevMan5.4.1.Results：Nineteen studies involving1728 patients were included.Meta-analysis showedthatthetrialgroupexhibited highertotaleffectiverateand maximum urinary flow rate（Qmax） than the control group [OR =3.83 ， 95% CI （2.78，5.27）， P<0.00001 MD=2.52 ， 95% CI（1.53，3.50）， P<0.000 01 ]，and lower International Prostate Symptom Score（IPSS），post-void residual urine volume（PVR），prostate volume（PV），and quality-of-life index（QOL）scores [MD 1=-3.72 ，95%CI （-4.40， -3.05）， P<0.00001 ；MD =-6.71 ， 95%CI （ -8.59 ， -4.83AA ， P<0.00001 . MD=-3.07 ，95%CI（-4.56，-1.57）， P<0.000 1 ；MD=-0.86， 95% CI （-1.07， -0.64） ， P<0.000 01]. Conclusion： Bushen Huoxue Huayu therapy is superior to conventional western medicine alone in improving total efective rateand Qmax，and in reducing IPSS， PVR，PV，and QOL scores for patients with BPH.

Keywords：Benign prostatic hyperplasia；Bushen Huoxue Huayu therapy；Clinical efficacy；Meta-analysis

中老年男性（年龄 ⩾50 岁）常见的前列腺病变为良性前列腺增生（BPH），其病理特征为前列腺间质和腺体组织的增生，以及前列腺体积的增大。（剩余9849字）